EP3464608A4 - Protéines klotho recombinées thérapeutiques et compositions et méthodes comprenant celles-ci - Google Patents
Protéines klotho recombinées thérapeutiques et compositions et méthodes comprenant celles-ci Download PDFInfo
- Publication number
- EP3464608A4 EP3464608A4 EP17807601.4A EP17807601A EP3464608A4 EP 3464608 A4 EP3464608 A4 EP 3464608A4 EP 17807601 A EP17807601 A EP 17807601A EP 3464608 A4 EP3464608 A4 EP 3464608A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- same
- methods involving
- therapeutic recombinant
- klotho proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000015834 Klotho Human genes 0.000 title 1
- 108050004036 Klotho Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
- C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
- C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
- C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
- C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01031—Beta-glucuronidase (3.2.1.31)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
- C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662344743P | 2016-06-02 | 2016-06-02 | |
US201662375046P | 2016-08-15 | 2016-08-15 | |
US201662401600P | 2016-09-29 | 2016-09-29 | |
US201662425237P | 2016-11-22 | 2016-11-22 | |
US201762456318P | 2017-02-08 | 2017-02-08 | |
PCT/US2017/035755 WO2017210607A1 (fr) | 2016-06-02 | 2017-06-02 | Protéines klotho recombinées thérapeutiques et compositions et méthodes comprenant celles-ci |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3464608A1 EP3464608A1 (fr) | 2019-04-10 |
EP3464608A4 true EP3464608A4 (fr) | 2020-01-29 |
Family
ID=60477890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17807601.4A Pending EP3464608A4 (fr) | 2016-06-02 | 2017-06-02 | Protéines klotho recombinées thérapeutiques et compositions et méthodes comprenant celles-ci |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP3464608A4 (fr) |
JP (2) | JP2019526272A (fr) |
KR (2) | KR20230125857A (fr) |
CN (2) | CN109219663A (fr) |
AU (1) | AU2017272349B2 (fr) |
BR (1) | BR112018073909A2 (fr) |
CA (1) | CA3025461A1 (fr) |
MX (2) | MX2018014753A (fr) |
WO (1) | WO2017210607A1 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019005687A (es) | 2016-11-22 | 2019-09-05 | Klotho Therapeutics Inc | Proteinas klotho recombinantes novedosas y composiciones y metodos que involucran a las mismas. |
CN108333355B (zh) * | 2018-02-01 | 2020-05-26 | 黄曙 | Klotho蛋白在制备诊断胃肠道间质瘤危险度的试剂中的用途 |
CN108384747A (zh) * | 2018-03-05 | 2018-08-10 | 安徽省农业科学院园艺研究所 | 表达狂犬抗体的cho细胞无血清悬浮培养方法 |
CN109251896A (zh) * | 2018-08-13 | 2019-01-22 | 中山大学 | 一株高表达hKLs-his蛋白的细胞株及其制备方法和应用 |
WO2020160617A1 (fr) * | 2019-02-05 | 2020-08-13 | Helium 3 Biotech Pty Ltd | Composition de modulation de l'expression et de la distribution de protéines membranaires et son procédé d'utilisation |
RU2712770C1 (ru) * | 2019-05-21 | 2020-01-31 | Всеволод Викторович Мелехин | Способ ингибирования роста опухолевых клеток |
IT201900007446A1 (it) | 2019-05-29 | 2020-11-29 | Giuseppe Castellano | Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho |
US11891615B2 (en) | 2020-06-10 | 2024-02-06 | Gail Marion Humble | Process to produce Klotho protein in vitro |
CN112195165A (zh) * | 2020-10-15 | 2021-01-08 | 广东药科大学 | 一种抗衰老分泌型Klotho蛋白及其编码基因、重组表达载体与应用 |
CN114487218B (zh) * | 2020-10-23 | 2023-11-14 | 北京红惠新医药科技有限公司 | β-烟酰胺单核苷酸的分析方法 |
CN112915193B (zh) * | 2021-03-05 | 2022-09-13 | 南方医科大学南方医院 | Kp-1在制备治疗慢性肺病的药物中的用途 |
CN113444730A (zh) * | 2021-03-17 | 2021-09-28 | 昆明市延安医院 | 一种原发性肝细胞klotho基因转导干细胞筛选构建方法 |
CN113215199A (zh) * | 2021-04-29 | 2021-08-06 | 广州博识生物科技有限公司 | 一种Klotho+/-基因缺失斑马鱼 |
CA3218655A1 (fr) * | 2021-05-21 | 2022-11-24 | Joan ROIG SORIANO | Variant d'epissage secrete de klotho pour le traitement de troubles osseux |
CN113409306A (zh) * | 2021-07-15 | 2021-09-17 | 推想医疗科技股份有限公司 | 一种检测装置、训练方法、训练装置、设备和介质 |
WO2023172444A2 (fr) * | 2022-03-08 | 2023-09-14 | Mayo Foundation For Medical Education And Research | Agents sénothérapeutiques et polypeptides alpha-klotho |
WO2023218445A1 (fr) * | 2022-05-08 | 2023-11-16 | Ichilov Tech Ltd. | Dérivés de klotho à structure modifiée |
WO2024115728A1 (fr) * | 2022-12-02 | 2024-06-06 | Universitat Autònoma De Barcelona | Variant d'épissage sécrété de klotho pour le traitement de troubles musculaires |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000027885A1 (fr) * | 1998-11-05 | 2000-05-18 | Kyowa Hakko Kogyo Co., Ltd. | Nouveau popypeptide chimerique |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05006522A (es) * | 2002-12-23 | 2006-02-17 | Bristol Myers Squibb Co | Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina. |
TW200936156A (en) * | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
CN102861343A (zh) * | 2012-10-17 | 2013-01-09 | 南方医科大学 | 分泌型Klotho在制备治疗慢性肾脏病的药物中的应用 |
MY184699A (en) * | 2014-04-16 | 2021-04-18 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
-
2017
- 2017-06-02 BR BR112018073909-0A patent/BR112018073909A2/pt unknown
- 2017-06-02 CN CN201780034374.7A patent/CN109219663A/zh active Pending
- 2017-06-02 WO PCT/US2017/035755 patent/WO2017210607A1/fr unknown
- 2017-06-02 EP EP17807601.4A patent/EP3464608A4/fr active Pending
- 2017-06-02 KR KR1020237028237A patent/KR20230125857A/ko active Application Filing
- 2017-06-02 KR KR1020187034860A patent/KR102570250B1/ko active IP Right Grant
- 2017-06-02 CN CN202310383190.9A patent/CN116478907A/zh active Pending
- 2017-06-02 AU AU2017272349A patent/AU2017272349B2/en active Active
- 2017-06-02 JP JP2019515786A patent/JP2019526272A/ja active Pending
- 2017-06-02 CA CA3025461A patent/CA3025461A1/fr active Pending
- 2017-06-02 MX MX2018014753A patent/MX2018014753A/es unknown
-
2018
- 2018-11-29 MX MX2023008626A patent/MX2023008626A/es unknown
-
2023
- 2023-06-12 JP JP2023096236A patent/JP2023123565A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000027885A1 (fr) * | 1998-11-05 | 2000-05-18 | Kyowa Hakko Kogyo Co., Ltd. | Nouveau popypeptide chimerique |
Non-Patent Citations (2)
Title |
---|
KATO YUKINARI ET AL: "Establishment of the anti-Klotho monoclonal antibodies and detection of Klotho protein in kidneys", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 267, no. 2, 19 January 2000 (2000-01-19), pages 597 - 602, XP002572556, ISSN: 0006-291X, DOI: 10.1006/BBRC.1999.2009 * |
YAMAZAKI Y ET AL: "Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjects", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 398, no. 3, 30 July 2010 (2010-07-30), pages 513 - 518, XP027185031, ISSN: 0006-291X, [retrieved on 20100701], DOI: 10.1016/J.BBRC.2010.06.110 * |
Also Published As
Publication number | Publication date |
---|---|
KR20230125857A (ko) | 2023-08-29 |
JP2023123565A (ja) | 2023-09-05 |
KR102570250B1 (ko) | 2023-08-29 |
JP2019526272A (ja) | 2019-09-19 |
BR112018073909A2 (pt) | 2019-02-26 |
KR20190015711A (ko) | 2019-02-14 |
MX2018014753A (es) | 2019-06-17 |
EP3464608A1 (fr) | 2019-04-10 |
AU2017272349A1 (en) | 2018-11-22 |
CN109219663A (zh) | 2019-01-15 |
CA3025461A1 (fr) | 2017-12-07 |
AU2017272349B2 (en) | 2022-12-01 |
MX2023008626A (es) | 2023-08-08 |
WO2017210607A1 (fr) | 2017-12-07 |
CN116478907A (zh) | 2023-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3464608A4 (fr) | Protéines klotho recombinées thérapeutiques et compositions et méthodes comprenant celles-ci | |
EP3551212A4 (fr) | Nouvelles protéines klotho recombinées et compositions et méthodes les comprenant | |
EP3623388A4 (fr) | Protéine recombinante bispécifique et son utilisation | |
HK1257373A1 (zh) | 雙功能蛋白質和包含其的藥物組合物 | |
EP3538561A4 (fr) | Polypeptides de variant guidés par arn et leurs procédés d'utilisation | |
EP3380125A4 (fr) | Conjugués comprenant des groupes peptidiques et procédés associés à ceux-ci | |
EP3454832A4 (fr) | Protéines de fusion gdf15 et leurs utilisations | |
EP3235830A4 (fr) | Complexe protéine-interleukine 15 et utilisation associée | |
IL265489B (en) | Recombinant binding proteins and their uses | |
EP3633034A4 (fr) | PROTÉINE Cas9 MODIFIÉE, ET APPLICATION ASSOCIÉE | |
EP3596104A4 (fr) | Compositions comprenant des peptides courts dérivés du pedf et leurs utilisations | |
EP3310376A4 (fr) | Agents thérapeutiques modifiés et compositions associées | |
EP3518971A4 (fr) | Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations | |
EP3536792A4 (fr) | Levure recombinée et utilisation associée | |
EP3678701A4 (fr) | Compositions protéiques thérapeutiques et procédés de préparation et d'utilisation de celles-ci | |
EP3444270A4 (fr) | Nouvelle protéine naturelle et son application | |
EP3290441A4 (fr) | PROTÉINE DE LIAISON À RGMa ET SON UTILISATION | |
EP3393586A4 (fr) | Thérapie d'association par inhibiteur de bromodomaine et de protéine extra-terminale | |
EP3642219A4 (fr) | Compositions peptidiques et procédés associés | |
EP3436467A4 (fr) | Nouvelles compositions et méthodes thérapeutiques | |
EP3722305A4 (fr) | Protéine de fusion hm-3 et son utilisation | |
EP3708661A4 (fr) | Protéine de fusion d'enzyme thérapeutique à nouvelle structure et son utilisation | |
ZA202101250B (en) | Novel crispr-associated protein and use thereof | |
EP3523321A4 (fr) | Compositions et procédés d'expression et d'administration de protéines | |
EP4013445A4 (fr) | Compositions de protéines thérapeutiques et procédés correspondants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20181212 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200108 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/18 20060101ALI20191220BHEP Ipc: A61K 38/22 20060101ALI20191220BHEP Ipc: C12P 21/06 20060101AFI20191220BHEP Ipc: A61K 38/17 20060101ALI20191220BHEP |